PD-1/VEGF – Talk Bio

Actionable Insights Powered by AI

AbbVie Pays $650M Upfront to RemeGen for PD-1/VEGF Bispecific RC148 Rights Outside China

2 weeks ago talkbio0Tagged AbbVie, Antibodies, Bispecific, Neoplasms, PD-1/VEGF, RC148, RemeGen

AbbVie; RemeGen; RC148; PD-1/VEGF; bispecific antibody; oncology; licensing deal; $650M; $5.6B

AbbVie Raises 2025 Guidance and Eyes Strategic Deals in Neuroscience, Obesity, and Oncology

6 months ago talkbio0Tagged AbbVie, Advice, earnings, Neuroscience discipline, Obesity, PD-1/VEGF, Strategic Deals

AbbVie; 2025 guidance; earnings; neuroscience; obesity; PD-1/VEGF; strategic deals; pharmaceuticals

Akeso, Summit’s PD-1/VEGF bispecific records another pivotal study win in NSCLC

9 months ago talkbio0Tagged Akeso, Combined, Ivonescimab, Keytruda, Non-Small Cell Lung Carcinoma, PD-1/VEGF, Pharmacotherapy, Safety, summit

Ivonescimab, Non-Small Cell Lung Carcinoma, Akeso, PD-1/VEGF, Keytruda, summit, Pharmacotherapy, Combined, Safety

Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations

11 months ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug, Antibody-Drug Conjugates, Clinical Trials, Ivonescimab, PD-1/VEGF, Pfizer, Solid Neoplasm, summit

Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates (ADCs), PD-1/VEGF bispecific antibody, solid tumors, clinical trials